ARTICLE | Financial News
Follow-on roundup: Myovant, CytomX, Spero
July 13, 2018 6:14 PM UTC
Myovant Sciences Ltd. (NYSE:MYOV), CytomX Therapeutics Inc. (NASDAQ:CTMX) and Spero Therapeutics Inc. (NASDAQ:SPRO) each priced follow-ons late Thursday, raising a total of $275 million.
Myovant raised $75 million through the sale of 3.3 million shares at $22.50 in a follow-on underwritten by J.P. Morgan, Goldman Sachs, Barclays, JMP Securities and Baird. The price is a 7% discount to its close of $24.10 on Wednesday, when it proposed the follow-on after trading hours. Myovant shed 4% on Thursday, and then slipped another $2.05 to $21 on Friday...